Amylyx Pharmaceuticals, Inc. (AMLX) insider trading.
In Q3 2026, insiders at Amylyx Pharmaceuticals, Inc. reported 19 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 12 sales worth $3.5M.
- Transactions
- 19
- Purchases (P)
- 0
- Sales (S)
- 12
- Net shares, P minus S
- -121,302
- Insiders
- 6
- Last filed
- 2026-09-14
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Mazzariello Gina | Officer · Chief Legal Officer | 5 | 0 | 4 |
| Klee Justin B. | Director, Officer · Co-Chief Executive Officer | 3 | 0 | 2 |
| Cohen Joshua B | Director, Officer · Co-Chief Executive Officer | 3 | 0 | 2 |
| Frates James M | Officer · Chief Financial Officer | 3 | 0 | 2 |
| Bedrosian Camille L | Officer · Chief Medical Officer | 3 | 0 | 2 |
| Firestone Karen | Director | 2 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-10 | Klee Justin B. | S (D) | 1,439 | $33.16 | 3,613,056 | Form 4 |
| 2026-09-10 | Klee Justin B. | S (D) | 29,025 | $32.13 | 3,614,495 | Form 4 |
| 2026-09-10 | Cohen Joshua B | S (D) | 919 | $33.15 | 3,613,123 | Form 4 |
| 2026-09-10 | Cohen Joshua B | S (D) | 29,545 | $32.16 | 3,614,042 | Form 4 |
| 2026-09-10 | Mazzariello Gina | S (D) | 9,525 | $32.46 | 190,849 | Form 4 |
| 2026-09-10 | Mazzariello Gina | S (D) | 11 | $33.34 | 190,838 | Form 4 |
| 2026-09-10 | Frates James M | S (D) | 9,768 | $32.27 | 234,667 | Form 4 |
| 2026-09-10 | Frates James M | S (D) | 1,042 | $33.23 | 233,625 | Form 4 |
| 2026-09-10 | Bedrosian Camille L | S (D) | 7,947 | $32.21 | 280,145 | Form 4 |
| 2026-09-10 | Bedrosian Camille L | S (D) | 2,081 | $33.09 | 278,064 | Form 4 |
| 2026-08-31 | Firestone Karen | M (A) | 25,000 | $1.76 | 91,900 | Form 4 |
| 2026-08-31 | Firestone Karen | M (A) | 25,000 | $5.05 | 116,900 | Form 4 |
| 2026-08-18 | Cohen Joshua B | A (A) | 60,039 | $0 | 3,643,587 | Form 4 |
| 2026-08-18 | Bedrosian Camille L | A (A) | 22,807 | $0 | 288,092 | Form 4 |
| 2026-08-18 | Mazzariello Gina | A (A) | 21,284 | $0 | 200,374 | Form 4 |
| 2026-08-18 | Klee Justin B. | A (A) | 60,039 | $0 | 3,643,520 | Form 4 |
| 2026-08-18 | Frates James M | A (A) | 22,807 | $0 | 244,435 | Form 4 |
| 2026-07-10 | Mazzariello Gina | S (D) | 15,000 | $17.61 | 179,090 | Form 4 |
| 2026-07-09 | Mazzariello Gina | S (D) | 15,000 | $18.32 | 194,090 | Form 4 |
Transaction codes in this quarter
Get AMLX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1658551&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · AMLX company page · Amylyx Pharmaceuticals, Inc. on SEC.gov
Questions
Are insiders buying or selling Amylyx Pharmaceuticals, Inc. (AMLX)?
In Q3 2026, insiders at Amylyx Pharmaceuticals, Inc. reported 19 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 12 sales worth $3.5M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Amylyx Pharmaceuticals, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/amlx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.